Bristol-Myers Squibb: Milvex Event Rates – May Get a Timing Update in NT – Incremental Positive if Pushed Based on Our Stats Analysis Simulation Scenario
Report Coverage
- Broker
- UBS
- Region
- United States
- Sector
- Healthcare & Biotech
- Report Type
- Company Report
- Primary Focus
- Milvexian Phase III AFib trial event rate and timing update
Report Summary
UBS highlights that Bristol-Myers Squibb management may provide an updated timing for the milvexian Phase III AFib trial (LIBREXIA-AF) as early as the Q2 call. Based on UBS statistical analysis, if the trial timeline is pushed to early 2027, it would imply the hazard ratio is tracking at or below the non-inferiority cut-off of 1.13, increasing UBS's probability of success from 35-50% to 50-55%. Milvexian remains one of the key catalysts for BMY with $5-10B+ peak sales potential to offset Eliquis loss of exclusivity.
Key Takeaways
- If milvexian AFib trial timing is pushed to early 2027, it implies stroke HR is tracking below the 1.13 non-inferiority cut-off, which would be incrementally positive
- UBS raises probability of success (PoS) for stroke non-inferiority to 50-55% under the delayed-timing scenario, up from 35-50%
- Milvexian Phase III AFib data remains one of the major catalysts for BMY (with JNJ sharing economics), with $5-10B+ peak potential to offset Eliquis LOE
Why This Report Matters
Milvexian represents one of the most anticipated binary events in pharma in 2026. A positive readout could unlock $5-10B+ in peak sales for BMY and help offset the looming Eliquis cliff. The potential timing update, if pushed to early 2027, carries meaningful positive signal value as it implies better-than-expected efficacy based on UBS's statistical modeling, potentially moving PoS above 50% and driving a significant re-rating of BMY shares.
Topics Covered
Companies Mentioned
Who this summary is for
This summary is for users researching the UBS Bristol-Myers Squibb report. It helps users review Bristol-Myers Squibb: Milvex Event Rates – May Get a Timing Update in NT – Incremental Positive if Pushed Based on Our Stats Analysis Simulation Scenario coverage, key takeaways, and related broker or sector research paths across Milvexian Phase III AFib trial, Eliquis loss of exclusivity, Non-inferiority statistical analysis; Bristol-Myers Squibb, Johnson & Johnson.
Related Search Paths
Use these links to find similar broker research summaries and sector report notes.